Horizon Pharma's Unsustainable Business Model
News | 15 August 2012
Horizon Pharma (HZNP) currently has two FDA approved products, one of which is also approved in select EU countries. I view this company as significantly overvalued given that its products have no data suggestion superiority claims over cheap generics.
Click on the link to read the full article at Seeking Alpha
(This link will open in a new window)
- Encouraging results with Sangamo's SB-728-T in HIV treatment
- Bristol-Myers' data on Yervoy and nivolumab causes a stir
- Boehringer Ingelheim transitions to propellant-free Combivent Respimat; names new BMD member
- Sanofi prepares for regulatory filing of MF candidate on positive JAKARTA study results
- Neovacs moving forward in rheumatoid arthritis, say analysts
